Narsoplimab

Summary

Narsoplimab (CHEMBL4298195) is a phase-3 clinical-stage antibody targeting MASP2; indicated across 4 conditions including iga glomerulonephritis and atypical hemolytic-uremic syndrome.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Targets: 1 (MASP2)
• Indications: 4 conditions
• Clinical trials: 8

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4298195
Name	Narsoplimab
Type	Antibody
Max phase	3

Also known as: Masp-2 antibody, Narsoplimab, OMS-721, OMS00620646, OMS620646, OMS721, NARSOPLIMAB

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
MASP2	MBL associated serine protease 2	Binding	10.05	0.6%	O00187

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): MASP2.

Top Reactome pathways

4 total, by targets touching each:

Pathway	Targets	Genes
Lectin pathway of complement activation	1	MASP2
Initial triggering of complement	1	MASP2
Ficolins bind to repetitive carbohydrate structures on the target cell surface	1	MASP2
SARS-CoV-2 activates/modulates innate and adaptive immune responses	1	MASP2

Dominant GO biological processes

GO term	Targets
complement activation, lectin pathway	1
proteolysis	1
complement activation, classical pathway	1
immune system process	1
complement activation	1
humoral immune response	1
innate immune response	1

Indications & clinical

Indications

4 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
IgA glomerulonephritis	3	MONDO:0005342	EFO:0004194
atypical hemolytic-uremic syndrome	3	MONDO:0016244	MONDO:0016244
lupus nephritis	2	MONDO:0005556	EFO:0005761
severe acute respiratory syndrome	2	MONDO:0005091	MONDO:0100096

Clinical trials

Total trials: 8.

Phase distribution

Phase	Trials
PHASE2	4
PHASE3	2
Not specified	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03205995	PHASE3	TERMINATED	Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrome
NCT03608033	PHASE3	TERMINATED	Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy
NCT04488081	PHASE2	ACTIVE_NOT_RECRUITING	I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients
NCT05855083	PHASE2	RECRUITING	Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMA
NCT02222545	PHASE2	COMPLETED	Safety and Efficacy Study of OMS721 in Patients With Thrombotic Microangiopathies
NCT02682407	PHASE2	TERMINATED	Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721
NCT02355782	Not specified	AVAILABLE	OMS721 Compassionate Use in Patients With Thrombotic Microangiopathy
NCT04247906	Not specified	APPROVED_FOR_MARKETING	Single Patient Expanded Access Treatment Plan For The Investigational Product Narsoplimab

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).